---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-046319"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2023-12-28T23:59:59+00:00"
generated_at: "2026-06-07T06:32:23.983394+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cingulate faces new Nasdaq delisting notice; halts CTx-1301 Phase 3 trials, plans NDA by H1 2025

## Summary
- Received additional Nasdaq non-compliance letter on Dec 26 due to three board resignations; hearing set for Feb 2024.
- Stopped enrollment in two Phase 3 pediatric ADHD studies for CTx-1301 after FDA guidance; NDA planned H1 2025 under 505(b)(2).
- Capital needed for CTx-1301 NDA reduced to $17-21M, $9-13M less than prior estimate.
- Needs to raise ~$15M by March 31, 2024 to regain compliance with Nasdaq minimum stockholders' equity rule.
- Board reduced to two non-independent directors; actively seeking new independent directors.

## SEC filing metadata
- accession: 0001493152-23-046319
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2023-12-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315223046319/0001493152-23-046319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315223046319/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-046319
- JSON: https://secwatch.observer/filing/0001493152-23-046319.json
- Plain text: https://secwatch.observer/filing/0001493152-23-046319.txt

## Key facts
- Listing & Compliance Notices
  Cingulate Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5605).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1), 5605
  source text: s non-compliance serves as additional and separate bases for desilting of our securities from Nasdaq. As previously disclosed, on November 14, 2023, we received a letter from Nasdaq indicating that, based upon our continued non-compliance the minimum stockholders’ equity requirement in Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”) for continued listing on Nasdaq, the Staff had determined to delist our securities from Nasdaq. We timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) and Nasdaq granted our request. At the Panel hearing, which is expected to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223046319/0001493152-23-046319-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.